Bioverativ installs new EVP of R&D
Bioverativ, a biotech company that develops therapies for rare blood disorders, announced the appointment of Tim Harris as Executive Vice President for Research and Development. He is tasked with directing Bioverativ’s scientific approach, advancing its pipeline programs and ensuring that its R&D programs are running efficiently.
He starts in the role effective immediately. The company noted his depth of experience when making the appointment and he carries behind him experience from working at numerous companies, particularly at Biogen. At Biogen, for five years he worked at a Senior Vice President of Precision Medicine and Senior Vice President of Translational Medicine and Biochemistry.
He also had experience of leading a 600-strong team of researchers at the SAIC-Frederick in advanced technologies in basic research applied to animal science. He formerly was CEO of SGX Pharmaceuticals, a company that was eventually acquired by Eli Lilly.
“Bioverativ has a world-class R&D organization that challenged the status quo and developed Eloctate and Alprolix, the first major advancements in haemophilia treatment in nearly 20 years,” said Dr. Harris. “It is an honour and a privilege to lead this outstanding team and I look forward to the opportunity to bring new, innovative medicines to patients through a focus on scientific innovation and clinical excellence.”
“I am excited to have Tim join the Bioverativ team,” said John Cox, CEO of Bioverativ. “Tim is an innovative and dynamic leader with tremendous scientific expertise across multiple therapeutic areas. He has a proven track record of leading R&D teams that push scientific boundaries, which will be instrumental in helping us rapidly advance our pipeline of novel programs for people with haemophilia, sickle cell disease and other rare blood disorders.”